首页> 外文OA文献 >Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer

【2h】

Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer

机译：聚合物递送的皮下升嘌呤醚醋酸酯制剂在晚期前列腺癌患者中实现并维持四项开放式研究中的睾酮浓度

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Neal D. Shore; Franklin Chu; Judd Moul; Daniel Saltzstein; Raoul Concepcion; John A. McLane; Stuart Atkinson; Alex Yang; E. David Crawford;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer [J] . Shore Neal D., Guerrero Silvia, Sanahuja Rosa M., Clinical therapeutics . 2019,第3期

机译：新的持续释放，3个月的嗜血糖乙酸醋酸酯配方达到并维持前列腺癌患者的睾酮浓度
2. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. [J] . Marberger M, Kaisary AV, Shore ND, Clinical therapeutics . 2010,第4期

机译：新型缓释醋酸亮丙瑞林3.75 mg储库制剂在前列腺癌患者中抑制睾丸激素的有效性，药代动力学和安全性：一项III期，开放标签，国际多中心研究。
3. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl [J] . Crawford E. David, Moul Judd W., Sartor Oliver, Expert opinion on drug metabolism & toxicology . 2015,第9期

机译：醋酸亮丙瑞林的6个月缓释制剂用于治疗晚期前列腺癌：睾丸激素水平低于20 ng / dl
4. Pretreatment Serum Testosterone Level Can Predict Pathological Stage in Localized Prostate Cancer Patients Treated with Radical Prostatectomy [C] . T. Imamoto, H. Suzuki, S. Fukasawa, International Congress of Andrology . 2005

机译：预处理血清睾酮水平可以预测局部前列腺癌患者的病理阶段，其患有自由基前列腺切除术治疗
5. Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy [D] . TAKEI, Akinori 2019

机译：雄激素剥夺治疗的持续时间和最低20 ng / dL的睾丸激素最低值可预测接受外照射的前列腺癌患者的睾丸激素恢复至超水平
6. Correction for Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients [O] . 2019

机译：对皮下注射醋酸亮丙瑞林在前列腺癌患者中达到低谷睾丸激素的功效的更正
7. A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients [O] . Neal Shore, Ivan Mincik, Mark DeGuenther, 2019

机译：在晚期前列腺癌症患者中，3个月预混合仓库制剂的6个月前仓库制剂的阶段3，开放标签，开放标签的多中心研究

Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer

著录项

引文网络

相似文献

相关主题

期刊订阅